Pricing Log in Create free account

Hemab Therapeutics Holdings, Inc. (COAG) vs Trevi Therapeutics, Inc. (TRVI)

Hemab Therapeutics Holdings, Inc. and Trevi Therapeutics, Inc. are both Biotechnology companies. Hemab Therapeutics Holdings, Inc. is the larger, with a market value of $2.1B against $1.8B — 1.2× the size. Across the 7 metrics below, Trevi Therapeutics, Inc. leads on 4 and Hemab Therapeutics Holdings, Inc. on 3.

Valuation

Metric COAG TRVI Biotechnology median
P/E n/m n/m 10.26
P/S n/m n/m 9.18
P/B 3.03 6.30 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m n/m 8.98
Earnings yield (117.82%) (2.63%) (34.89%)
Free cash flow yield (5.28%) (2.61%) (24.52%)

Profitability

Metric COAG TRVI Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (19.66%) (50.12%)
Return on assets (31.79%) (18.97%) (45.60%)
Return on invested capital 0.00% (1,412.11%) 0.00%

Growth

Metric COAG TRVI Biotechnology median
Revenue growth (TTM) — — 6.26%
EPS growth (last fiscal year) — 31.91% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric COAG TRVI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 35.85 37.28 4.89
Net debt to EBITDA — 3.83 1.01

Dividend

Metric COAG TRVI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric COAG TRVI Biotechnology median
Market cap 2.13b 1.83b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack